Evotec and Dewpoint Therapeutics enter strategic partnership
Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s oncology pipeline programmes of condensate modifying therapeutics (c-mods) to Investigational New Drug Applications (INDs) through the use of Evotec’s fully integrated data-driven platform (INDiGO).
The partnership is intended to bring together Dewpoint’s advanced oncology pipeline programmes with Evotec’s ability to de-risk and accelerate pre-clinical development candidates to first-in-human clinical trials.
Under terms of the agreement, Evotec will facilitate the development of Dewpoint’s oncology assets using Evotec’s INDiGO platform to accelerate the path to clinical testing. This agreement is based on a risk-sharing arrangement followed by milestone and royalty payments to Evotec depending on the success of the overall programmes.
Dr Matthias Evers, chief business officer of Evotec, commented: “We are excited to enter this strategic development partnership with Dewpoint. Its innovative approach is based on a holistic understanding, which can significantly expand the target space across indications. By combining our complementary expertise, Evotec’s development platform will serve as the capital-efficient IND engine for this highly collaborative partnership. We look forward to working closely together with their team to make Dewpoint’s groundbreaking innovations available to patients.”
Genentech, a member of the Roche Group, has announced positive results from the phase 3 …
Transgene and BioInvent have announced that the first patient has been treated in the phase …